Lantheus (NASDAQ:LNTH) Stock Unloaded by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Lantheus Holdings, Inc. (NASDAQ:LNTH). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Lantheus stock on October 14th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

Lantheus Stock Down 0.3%

Shares of NASDAQ LNTH traded down $0.35 during trading hours on Thursday, hitting $101.25. The company had a trading volume of 1,193,845 shares, compared to its average volume of 1,099,041. The stock has a market capitalization of $6.62 billion, a P/E ratio of 18.75 and a beta of 0.01. The company has a quick ratio of 3.06, a current ratio of 3.25 and a debt-to-equity ratio of 0.42. The firm’s 50 day moving average is $100.31 and its 200-day moving average is $92.74. Lantheus Holdings, Inc. has a 1-year low of $51.47 and a 1-year high of $111.86.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.45. The business had revenue of $389.91 million for the quarter, compared to analysts’ expectations of $355.74 million. Lantheus had a return on equity of 29.26% and a net margin of 17.28%. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.27 EPS. On average, analysts expect that Lantheus Holdings, Inc. will post 4.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Brookline Capital Markets cut shares of Lantheus from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. CJS Securities lowered Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Leerink Partners set a $102.50 price objective on Lantheus in a research report on Monday, August 3rd. Weiss Ratings downgraded Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, October 15th. Finally, B. Riley Financial cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Monday, August 17th. Three equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $107.44.

Institutional Investors Weigh In On Lantheus

A number of hedge funds have recently made changes to their positions in the stock. Jupiter Topco LLC acquired a new position in Lantheus during the 2nd quarter worth approximately $575,628,000. Reinhart Partners LLC. lifted its holdings in Lantheus by 2.2% during the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after buying an additional 34,501 shares during the period. Carmignac Gestion lifted its stake in shares of Lantheus by 0.9% in the second quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider’s stock worth $148,671,000 after acquiring an additional 12,100 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Lantheus by 440.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after purchasing an additional 582,661 shares during the period. Finally, Epoch Investment Partners Inc. boosted its holdings in shares of Lantheus by 59.4% during the 1st quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock worth $49,284,000 after buying an additional 242,222 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Lantheus

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.